Company intelligence / Profile preview

AIM Vaccine

Dalian, China

Ownership: Private
Employees: ~400
Development stage: Other

Overview

AIM Vaccine has eight marketed vaccines and over 20 in clinical development, including leading positions in hepatitis B and rabies vaccines. Several key pipeline products (including mRNA RSV, mRNA shingles, and advanced pneumococcal and serum-free rabies vaccines) are in Phase 3 with strong data indicating superior immunogenicity and safety. The serum-free rabies vaccine and pneumococcal vaccines are nearing registration in China, and the mRNA pipeline includes China's first non-COVID mRNA vaccines accepted for review.[1][2][3]

Therapeutic areas: Infectious Diseases
Modalities: VaccinemRNA-based drugsRecombinant proteinProteinSmall molecule
Industry: Biotech

Partnerships

DeepSeek (AI R&D integration)[5]

Beyond the preview

Go deeper on AIM Vaccine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIM Vaccine.

Explore the full profile